HMBEI is a leading pharmaceutical and life sciences company dedicated to developing transformative therapies and accelerating discovery for a healthier world.
24+
Years Active
180+
Compounds
38
Countries
Scroll to explore
CLINICAL RESEARCH · DRUG DISCOVERY · BIOANALYSIS · REGULATORY AFFAIRS · PHARMACOVIGILANCE · LIFE SCIENCES · MOLECULAR BIOLOGY · GENOMICS · PRECISION MEDICINE · CLINICAL RESEARCH · DRUG DISCOVERY · BIOANALYSIS · REGULATORY AFFAIRS · PHARMACOVIGILANCE · LIFE SCIENCES · MOLECULAR BIOLOGY · GENOMICS · PRECISION MEDICINE ·
Who We Are
Science at the Core of Everything
Founded in Lugano, Switzerland, HMBEI operates at the intersection of pharmaceutical science, biotechnology, and clinical excellence. Our multidisciplinary teams work tirelessly to discover, develop, and deliver life-changing medicines to patients across the globe.
With state-of-the-art facilities in the Canton of Aargau and a global network of research partners, we are positioned at the frontier of modern medicine.
What We Do
Our Core Capabilities
Drug Discovery
Cutting-edge compound identification and lead optimization using AI-assisted molecular modeling and high-throughput screening platforms.
Clinical Trials
Phase I–IV clinical development with rigorous protocols, biostatistics support, and patient-centric trial designs across multiple therapeutic areas.
Regulatory Affairs
Expert navigation of EMA, FDA, and Swissmedic regulatory pathways including submission strategy, dossier preparation, and post-approval management.
Bioanalytical Services
GLP-compliant bioanalytical laboratory services including PK/PD analysis, immunogenicity assessment, and biomarker quantification.
Market Access
Health economics, outcomes research, and pricing strategy to maximize patient access and commercial success across European and global markets.
Pharmacovigilance
Comprehensive safety monitoring, adverse event management, SUSAR reporting, and risk management planning across the full product lifecycle.
Development Pipeline
From Discovery to Market
01
Discovery
Target ID & validation, HTS campaigns
02
Preclinical
ADME, tox studies, IND filing
03
Phase I–II
Safety, PK, proof-of-concept
04
Phase III
Pivotal efficacy & safety
05
Approval
NDA/MAA submission & launch
About HMBEI
Built on Science. Driven by Purpose.
Our Story
Shaping the Future of Medicine
HMBEI was founded with a singular vision: to harness the power of modern science to address unmet medical needs. From our headquarters in Lugano, Switzerland, we have grown into a globally recognized pharmaceutical and life sciences company with operations spanning 38 countries.
Our teams of over 1,200 scientists, clinicians, and regulatory experts collaborate across disciplines to push the boundaries of what is possible — from early-stage drug discovery to post-market surveillance.
Headquartered at Europaallee 8286, Apt 812, in the heart of Switzerland, HMBEI combines Swiss precision with global ambition to deliver therapies that truly matter.
Our Values
The Principles that Guide Us
01
Scientific Integrity
Every claim we make, every compound we advance, every study we conduct is held to the highest standards of scientific rigor and ethical conduct.
02
Patient Centricity
Patients are at the center of every decision we make. Their needs, voices, and outcomes guide our research priorities and development strategies.
03
Collaborative Innovation
We believe the best science emerges from open collaboration — with academic institutions, biotech partners, clinicians, and patient communities worldwide.
04
Global Responsibility
We are committed to equitable access to medicines, sustainable operations, and responsible stewardship of the trust placed in us by society.
Certifications & Compliance
ISO 9001:2015GMP CertifiedGLP CompliantICH Q10SwissmedicEMA Approved
Leadership
The Minds Behind HMBEI
Dr. Elena Richter
Chief Executive Officer
Dr. Marc Hollander
Chief Scientific Officer
Dr. Priya Anand
Head of Clinical Development
Services
Full-Spectrum Pharmaceutical Capabilities
Core Services
Expertise Across the Value Chain
From early discovery through commercialization, HMBEI provides integrated pharmaceutical services tailored to the complexity and scale of your program.
01
Drug Discovery & Development
AI-assisted target identification, fragment-based drug design, and fully integrated medicinal chemistry programs to optimize your lead compounds.
Target identification & validation
High-throughput screening (HTS)
Lead optimization & SAR analysis
Candidate selection & IND-enabling studies
02
Clinical Trial Management
End-to-end clinical trial execution from protocol design through database lock, with robust biostatistics and medical writing support.
Phase I–IV study design & management
Site selection & monitoring
Data management & biostatistics
Medical writing & reporting
03
Regulatory Strategy
Comprehensive regulatory consulting and submission management for EMA, FDA, Swissmedic, and emerging market health authorities.
Regulatory pathway strategy
CTD dossier preparation (eCTD)
Scientific advice meetings
Labeling & post-approval changes
04
Bioanalytical & DMPK
GLP-accredited laboratory offering method development, validation, and sample analysis for small molecules and biologics.
LC-MS/MS method development
Immunogenicity (ADA assays)
In vitro ADME profiling
PK/PD modeling & simulation
05
Pharmacovigilance
Robust safety monitoring systems and expert case management ensuring full compliance with ICH E2E and international reporting requirements.
Individual case safety reports (ICSRs)
Periodic benefit-risk reports (PBRERs)
Risk management plans (RMPs)
Signal detection & assessment
06
Market Access & HEOR
Evidence-based strategies to maximize patient access and demonstrate value to payers, HTA bodies, and healthcare systems.
Cost-effectiveness modeling
HTA submissions (NICE, HAS, AIFA)
Real-world evidence generation
Pricing & reimbursement strategy
How We Work
Our Engagement Process
01
Discovery Call & Needs Assessment
We begin with a focused consultation to understand your program, goals, and challenges — identifying the specific expertise and resources you need.
02
Proposal & Scope Definition
Our team develops a tailored proposal with detailed scope, timelines, resource allocation, and transparent pricing — typically within 5 business days.
03
Project Initiation & Team Assembly
A dedicated project manager is assigned, specialist teams are mobilized, and governance structures are established for seamless collaboration.
04
Execution & Continuous Reporting
Regular milestone reporting, transparent communication, and agile adaptation ensure your program stays on track and on budget throughout delivery.
Research & Development
Pioneering the Science of Tomorrow
Therapeutic Focus
Our Research Areas
Oncology
Immunology & Inflammation
Neuroscience
Rare Diseases
Cardiovascular
Oncology
Our oncology program focuses on targeted therapies and immuno-oncology approaches for solid tumors and hematologic malignancies. We leverage deep genomic profiling and biomarker-driven patient selection to maximize therapeutic impact and minimize off-target toxicity.
Current pipeline includes next-generation KRAS inhibitors, bispecific antibody-drug conjugates, and CAR-T cell therapies for refractory disease settings.
KRAS InhibitorsADCsImmuno-oncologyCAR-T
Immunology & Inflammation
We are advancing a pipeline of selective immunomodulators designed to restore immune homeostasis in autoimmune and inflammatory diseases. Our approach targets novel cytokine pathways and regulatory T cell biology to achieve durable remission.
JAK InhibitorsIL-17/23Treg Biology
Neuroscience
Our neuroscience program is exploring novel mechanisms in neurodegeneration, neuroinflammation, and psychiatric disorders. We partner with leading academic medical centers to translate cutting-edge neurobiology into new therapeutic options for patients with limited treatment choices.
NeurodegenerationTDP-43Synaptic Biology
Rare Diseases
We are committed to patients with rare and ultra-rare conditions who have few or no therapeutic options. Our rare disease program leverages gene therapy platforms, RNA-based therapeutics, and enzyme replacement strategies to address the root cause of disease.
Gene TherapyRNA TherapeuticsERT
Cardiovascular
Our cardiovascular portfolio focuses on metabolic drivers of heart failure, atherosclerosis, and thrombosis. We are developing first-in-class small molecules and siRNA-based therapies targeting lipid metabolism and vascular inflammation.
Lipid MetabolismsiRNAHeart Failure
Scientific Output
Selected Publications
2024
Selective KRAS G12C Inhibition in Advanced Non-Small Cell Lung Cancer: A Phase II Multicenter Study
Journal of Clinical Oncology · HMBEI Research Group et al.
2024
Next-Generation JAK1 Inhibitors with Improved Selectivity Profiles for Autoimmune Disease
Nature Chemical Biology · Hollander M, Richter E, et al.
2023
RNA-Based Therapeutic Strategies for Lysosomal Storage Disorders: Preclinical Validation
Cell Chemical Biology · Anand P, et al.
2023
Biomarker-Driven Patient Stratification in Phase III Oncology Trials: A Framework for Success
The Lancet Oncology · HMBEI Clinical Development Group
2022
Neuroinflammation and Synaptic Pruning: Novel Targets in Alzheimer's Disease Pathogenesis
Brain · Richter E, Müller K, et al.
Let's Start a Conversation
Address
Building 8286, Europaallee Apartment 812 96238 Lugano Canton of Aargau, Switzerland
Phone
+41-01-770-09-17
Website
hmbei.rest
Office Hours
Monday – Friday: 08:00 – 18:00 CET Saturday: 09:00 – 13:00 CET Sunday: Closed
Send Us a Message
Whether you're exploring partnership opportunities, seeking our services, or have a scientific inquiry — our team will respond within 2 business days.
✓ Thank you for reaching out. Our team will be in touch within 2 business days.
